Related Experiment Video
Updated: Jun 6, 2026
10:37
Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
[Analogs combination therapy in chronic hepatitis B: when and how?]
A Kahloun1, M Bourlière, F Zoulim
1Service d'Hépato-gastroentérologie Hôpital Saint Joseph, Marseille, France.
Gastroenterologie Clinique Et Biologique
|November 25, 2010
Summary
Hepatitis B virus (HBV) genomic variability complicates treatment. Combination therapy can prevent drug resistance, but long-term benefits require further study, especially for high genetic barrier drugs.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- Hepatitis B virus (HBV) genomic variability drives viral evolution and drug resistance.
- Persistent infections facilitate the selection of resistant HBV strains.
- Nucleoside analogs without cross-resistance support combination therapy strategies.
Purpose of the Study:
- To evaluate the efficacy of de novo combination therapy versus add-on strategies for managing HBV infection.
- To determine the long-term benefits of de novo combination therapy, particularly with high genetic barrier drugs.
- To assess optimal timing for implementing add-on strategies to prevent virological breakthrough.
Main Methods:
- Review of existing literature on HBV treatment strategies.
- Analysis of clinical trial data on combination therapy and add-on approaches.
- Comparative assessment of drug resistance emergence under different therapeutic regimens.
Main Results:
- De novo combination with low genetic barrier drugs shows short-term efficacy in preventing resistance and controlling infection.
- Long-term outcomes for de novo combination with high genetic barrier drugs remain to be determined.
- Early implementation of add-on strategies is crucial, especially with sub-optimal viral suppression.
Conclusions:
- Combination therapy offers a promising approach to combat HBV drug resistance.
- Further clinical trials are necessary to compare de novo combination with early add-on strategies.
- Optimizing treatment strategies is essential for long-term HBV management and preventing resistance.
More Related Videos
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
09:35Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
Published on: February 1, 2017
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
01:27Combined Effects of Drugs: Synergism
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...